Article Details

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies

Retrieved on: 2021-08-01 15:48:16

Tags for this article:

Click the tags to see associated articles and topics

Dr. Kelly on Overcoming Osimertinib Resistance in NSCLC With Bispecific Antibodies. View article details on hiswai:

Excerpt

However, the concern with utilizing a monoclonal antibody in this setting is that it will not cross the blood brain barrier, she says. As such lazertinib ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up